Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aeluma, Inc.ALMU · Entity 6202 | Director | August 26, 2026 | August 28, 2026 |
| Akoustis Technologies, Inc.AKTS · Entity 88229 | Director | November 06, 2023 | November 08, 2023 |
| Palomino Laboratories Inc.NONE · Entity 9910 | Director | April 20, 2026 | April 20, 2026 |
| SmartKem, Inc.SMTK · Entity 8554 | Director | September 03, 2025 | September 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aeluma, Inc.
Report date August 26, 2026 · Filed August 28, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 345,209 |
Last balance in matching sequence
After 2026-08-27 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-26 · Sale · Disposed 12,500 · Balance 357,709 F1: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2025. F2: The price reported in Column 4 represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.57 to $14.40, inclusive. Row 2 · 2026-08-27 · Sale · Disposed 12,500 · Balance 345,209 F1: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2025. F3: The price reported in Column 4 represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.59 to $14.35, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2025.
F2: The price reported in Column 4 represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.57 to $14.40, inclusive.
F3: The price reported in Column 4 represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.59 to $14.35, inclusive.
Akoustis Technologies, Inc.
Report date November 06, 2023 · Filed November 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 325,959 |
Reported balance
After 2023-11-06 transaction · row 1
1 source rowRow 1 · 2023-11-06 · Grant · Acquired 38,250 · Balance 325,959 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2030-11-06 | Direct | 76,500 |
Reported balance
After 2023-11-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-06 · Grant · Acquired 76,500 · Balance 76,500 |
Palomino Laboratories Inc.
Report date April 20, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,762,500 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Purchase · Acquired 12,500 · Balance 1,762,500 |
SmartKem, Inc.
Report date September 03, 2025 · Filed September 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2035-09-03 | Direct | 22,466 |
Reported balance
After 2025-09-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-03 · Grant · Acquired 22,466 · Balance 22,466 F1: The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on September 3, 2025 and on the 3rd date of each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on September 3, 2025 and on the 3rd date of each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2018 Filed Nov 2, 2018 21:57 UTC | Akoustis Technologies, Inc. AKTS · Entity 88229 | GrantStock Option (Right to Buy) · Derivative | 22,748 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001615774-18-012045 · ownership.xml · derivative · entry 2 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,748 Underlying: Common Stock · 22,748 shares Expires 2025-10-31 Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 21:57 UTC | Akoustis Technologies, Inc. AKTS · Entity 88229 | GrantCommon Stock | 11,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-012045 · ownership.xml · nonDerivative · entry 1 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,432 F1 · balance_after: The balance reflects an adjustment to correct a computational error in column 5 of the reporting person's Form 4 filed March 19, 2018. Read SEC document |
| March 16, 2018 Filed Mar 19, 2018 19:00 UTC | Akoustis Technologies, Inc. AKTS · Entity 88229 | SaleCommon Stock | 4,000 | $6.03 | $24,120.00 |
DisclosureSEC source: 0001615774-18-001983 · s109404_form4.xml · nonDerivative · entry 2 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,424 F1 · shares: Shares sold to fund federal and state individual tax obligations. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.03 to $6.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 19:00 UTC | Akoustis Technologies, Inc. AKTS · Entity 88229 | SaleCommon Stock | 16,254 | $6.15 | $99,962.10 |
DisclosureSEC source: 0001615774-18-001983 · s109404_form4.xml · nonDerivative · entry 1 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,424 F1 · shares: Shares sold to fund federal and state individual tax obligations. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 16, 2017 Filed Nov 16, 2017 18:05 UTC | Akoustis Technologies, Inc. AKTS · Entity 88229 | GrantStock Option (Right to Buy) · Derivative | 32,732 | $0.00 Strike: $6.24 | $0.00 |
DisclosureSEC source: 0001615774-17-006801 · s108199_form4.xml · derivative · entry 3 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,732 Underlying: Common Stock · 32,732 shares Expires 2024-11-15 Read SEC document |
| November 16, 2017 Filed Nov 16, 2017 18:05 UTC | Akoustis Technologies, Inc. AKTS · Entity 88229 | GrantCommon Stock | 16,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-17-006801 · s108199_form4.xml · nonDerivative · entry 2 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,678 Read SEC document |
| November 16, 2017 Filed Mar 19, 2018 18:08 UTC Amendment | Akoustis Technologies, Inc. AKTS · Entity 88229 | GrantStock Option (Right to Buy) · Derivative | 32,732 | $0.00 Strike: $6.24 | $0.00 |
DisclosureSEC source: 0001615774-18-001982 · s109410_form4a.xml · derivative · entry 3 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,732 Underlying: Common Stock · 32,732 shares Expires 2024-11-15 Read SEC document |
| November 16, 2017 Filed Mar 19, 2018 18:08 UTC Amendment | Akoustis Technologies, Inc. AKTS · Entity 88229 | GrantCommon Stock | 16,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001982 · s109410_form4a.xml · nonDerivative · entry 2 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,678 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 18:05 UTC | Akoustis Technologies, Inc. AKTS · Entity 88229 | PurchaseCommon Stock | 5,454 | $5.50 | $29,997.00 |
DisclosureSEC source: 0001615774-17-006801 · s108199_form4.xml · nonDerivative · entry 1 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,312 Read SEC document |
| November 14, 2017 Filed Mar 19, 2018 18:08 UTC Amendment | Akoustis Technologies, Inc. AKTS · Entity 88229 | GrantCommon Stock | 5,454 | $5.50 | $29,997.00 |
DisclosureSEC source: 0001615774-18-001982 · s109410_form4a.xml · nonDerivative · entry 1 Denbaars Steven · CIK 0001700533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,312 F1 · kind: This amendment is being filed solely to correct the transaction code to reflect that the reporting person received the shares in an acquisition from the issuer in accordance with Exchange Act Rule 16b-3(d)(1). No other changes have been made to this form. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.